Synlogic (SYBX) Competitors $1.20 0.00 (-0.33%) Closing price 07/3/2025 01:00 PM EasternExtended Trading$1.20 0.00 (-0.08%) As of 07/3/2025 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. RENB, VTGN, CNTB, OTLK, IZTC, IRD, PMVP, NRXP, GNTA, and SNTIShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Renovaro (RENB), VistaGen Therapeutics (VTGN), Connect Biopharma (CNTB), Oncobiologics (OTLK), Invizyne Technologies (IZTC), Opus Genetics (IRD), PMV Pharmaceuticals (PMVP), NRx Pharmaceuticals (NRXP), Genenta Science (GNTA), and Senti Biosciences (SNTI). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Its Competitors Renovaro VistaGen Therapeutics Connect Biopharma Oncobiologics Invizyne Technologies Opus Genetics PMV Pharmaceuticals NRx Pharmaceuticals Genenta Science Senti Biosciences Renovaro (NASDAQ:RENB) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, dividends, analyst recommendations, institutional ownership, earnings and risk. Is RENB or SYBX more profitable? Synlogic's return on equity of 10.91% beat Renovaro's return on equity.Company Net Margins Return on Equity Return on Assets RenovaroN/A -60.38% -47.04% Synlogic N/A 10.91%7.47% Does the media favor RENB or SYBX? In the previous week, Renovaro had 4 more articles in the media than Synlogic. MarketBeat recorded 4 mentions for Renovaro and 0 mentions for Synlogic. Renovaro's average media sentiment score of 0.42 beat Synlogic's score of 0.00 indicating that Renovaro is being referred to more favorably in the media. Company Overall Sentiment Renovaro Neutral Synlogic Neutral Which has more volatility & risk, RENB or SYBX? Renovaro has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Which has higher valuation and earnings, RENB or SYBX? Synlogic has higher revenue and earnings than Renovaro. Synlogic is trading at a lower price-to-earnings ratio than Renovaro, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRenovaroN/AN/A-$88.43M-$0.77-0.36Synlogic$10K1,399.32-$23.36M-$2.51-0.48 Do institutionals & insiders believe in RENB or SYBX? 71.4% of Renovaro shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 21.7% of Renovaro shares are held by company insiders. Comparatively, 3.0% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryRenovaro beats Synlogic on 6 of the 11 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.80M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.24%4.01%P/E Ratio-0.4821.5627.6120.24Price / Sales1,399.32278.93417.30118.22Price / CashN/A42.7336.8958.10Price / Book1.107.518.035.67Net Income-$23.36M-$55.14M$3.18B$249.21M7 Day Performance-3.55%4.61%2.93%3.28%1 Month Performance-1.24%4.72%3.75%5.55%1 Year Performance-18.64%5.92%35.20%21.09% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic0.5202 of 5 stars$1.20-0.3%N/A-18.1%$13.80M$10K-0.4880Gap UpRENBRenovaro1.1447 of 5 stars$0.37+7.9%N/A-82.4%$58.76MN/A-0.4820High Trading VolumeVTGNVistaGen Therapeutics1.3795 of 5 stars$1.96-2.0%N/A-38.8%$58.31M$490K-1.1840CNTBConnect Biopharma3.3407 of 5 stars$0.98-5.3%$7.00+617.9%-15.3%$57.23M$26.03M0.00110News CoverageOTLKOncobiologics1.6735 of 5 stars$1.68-1.5%$9.60+471.4%-74.4%$57.23MN/A-1.8520IZTCInvizyne TechnologiesN/A$9.15-25.9%N/AN/A$57.21MN/A0.0029News CoverageGap UpIRDOpus Genetics1.6473 of 5 stars$0.91-4.6%$7.33+709.2%N/A$56.68M$10.99M-0.4314News CoverageGap DownPMVPPMV Pharmaceuticals3.0612 of 5 stars$1.07-1.8%$5.50+414.0%-22.4%$56.63MN/A-0.9150News CoverageNRXPNRx Pharmaceuticals2.0055 of 5 stars$3.10-4.9%$28.50+819.4%+28.3%$56.36MN/A-1.542GNTAGenenta Science1.8724 of 5 stars$3.06flat$25.00+717.0%N/A$55.97MN/A0.007SNTISenti Biosciences2.7063 of 5 stars$1.99-6.6%$8.50+327.1%-30.3%$55.55M$2.56M-0.184 Related Companies and Tools Related Companies Renovaro Competitors VistaGen Therapeutics Competitors Connect Biopharma Competitors Oncobiologics Competitors Invizyne Technologies Competitors Opus Genetics Competitors PMV Pharmaceuticals Competitors NRx Pharmaceuticals Competitors Genenta Science Competitors Senti Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
